Pfizer (PFE) Tops Q1 EPS by 10c; Bumps EPS Outlook

Go back to Pfizer (PFE) Tops Q1 EPS by 10c; Bumps EPS Outlook

PFIZER REPORTS FIRST-QUARTER 2019 RESULTS

April 30, 2019 6:45 AM EDT

First-Quarter 2019 Revenues of $13.1 Billion, Reflecting 5% Operational Growth Driven by 7% Operational Growth from Pfizer Biopharmaceuticals Group and 1% Operational Growth From Upjohn First-Quarter 2019 Reported Diluted EPS(1) of $0.68, Adjusted Diluted EPS(2) of $0.85 Raised Midpoint of 2019 Adjusted Diluted EPS(2) Guidance Range by $0.01 to $2.83 to $2.93, Primarily Reflecting Adjusted Other Income(2) Recorded During First-Quarter 2019, Partially Offset by the Unfavorable Impact of Foreign Exchange Reaffirmed 2019 Financial Guidance for Revenues

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2019 and... More